Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Squamous Cell Carcinoma of Head and Neck 10Melanoma 8Lung Neoplasms 8Neoplasms 7Carcinoma 6Skin Neoplasms 5Neoplasm Metastasis 5Carcinoma, Squamous Cell 5Carcinoma, Basal Cell 5Adenocarcinoma 5Sarcoma 4Mouth Neoplasms 4Head and Neck Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Recurrence 3Oropharyngeal Neoplasms 3Laryngeal Neoplasms 3Carcinoma, Merkel Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Hemangiosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2

Interventions

Cisplatin 51Gemcitabine 26toripalimab 20Radiotherapy, Intensity-Modulated 19Fluorouracil 16Capecitabine 16camrelizumab 15Docetaxel 14nimotuzumab 12Radiotherapy 10Drug Therapy 10apatinib 9Nivolumab 9sintilimab 8endostar protein 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Immune Checkpoint Inhibitors 7tislelizumab 6spartalizumab 6Chemoradiotherapy 6Cetuximab 6Bevacizumab 6pembrolizumab 5nedaplatin 5S 1 (combination) 5Radiation 5Paclitaxel 5Endostatins 5anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Carcinoma × cemiplimab × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡